HA
PASG icon

HC Advisors’s Passage Bio PASG Stock Holding History

HC Advisors’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-546
Closed -$144K – 85
2021
Q2 		$144K Buy
546
+34
+7% +$10.5K 0.09% 80
2021
Q1 		$179K Buy
+512
New +$219K 0.12% 84

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HC Advisors's PASG Position: Q3 2021 in Review

HC Advisors sold out of Passage Bio (PASG) in Q3 2021, closing a stake of 546 shares — an estimated $144K sold.

HC Advisors first reported a position in PASG in Q1 2021 and held it in 2 quarters. The position peaked at $179K in Q1 2021. 101 funds tracked by Wall St. Rank hold PASG as of Q3 2021.

  • HC Advisors reported no remaining Passage Bio position as of Q3 2021 after selling out during the quarter.
  • HC Advisors sold 546 Passage Bio shares in Q3 2021, an estimated $144K.
  • HC Advisors first reported a position in Passage Bio in Q1 2021 and held it in 2 quarters.
  • HC Advisors's Passage Bio position peaked at $179K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Passage Bio as of Q3 2021.

Based on HC Advisors's 13F filing for Q3 2021, filed 29 Oct 2021.